BIOMAG

Magnetic Biomaterials: Magnetically Loaded Stem Cells as Diagnostic and Therapeutic Vectors for Lung Cancer

Coordinatore	The Royal Institution of Great Britain    more  Organization address address: Albemarle Street 21 city: London postcode: W15 4BS contact info Titolo: Prof. Nome: Quentin Andrew Cognome: Pankhurst Email: send email Telefono: 44 7962 232 340 Fax: 44 20 7670 2920
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	0 €
EC contributo	181˙350 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IEF-2008
Funding Scheme	MC-IEF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-05-01   -   2011-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	The Royal Institution of Great Britain  Organization address address: Albemarle Street 21 city: London postcode: W15 4BS contact info Titolo: Prof. Nome: Quentin Andrew Cognome: Pankhurst Email: send email Telefono: 44 7962 232 340 Fax: 44 20 7670 2920	UK (London)	coordinator	181˙350.77

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Lung cancer is the most lethal cancer in the world today. There are limited options for clinicians when treating patients, with only 10-15% of lung cancer patients surviving their malignancy. Despite the introduction of new chemotherapies, lung cancer survival is unchanged from thirty years ago. New ways of treating this disease are needed. We hypothesise that modified mesenchymal stem cells (MSCs) may be used to deliver magnetic nanoparticles through their engraftment, killing both tumour epithelium and tumour vasculature, while preserving normal tissue. We propose to introduce bio-compatible tailored magnetic nanoparticles into the MSCs to enable localised cellular-level sensing and heating while retaining the full viability and functionality of the MSCs. We will examine the kinetics of MSC engraftment and compare histological samples to in vivo quantification of engraftment using contrast-enhanced small animal magnetic resonance imaging (MRI) based on sensing the MRI signal of the introduced nanoparticles. MSCs will subsequently be locally heated by applying a time-varying electromagnetic field to induce heating of the nanoparticles (a process similar in principle to that used in microwave ovens) and consequent tumour destruction. MSC delivered therapy is particularly attractive. MSCs are easy to culture, expand and genetically manipulate. They are immuno-privileged, and also home preferentially to tumour tissues allowing systemic delivery to widespread tumour and metastases. As such they offer a uniquely bio-compatible, patient-derived therapeutic solution to the life-threatening disease of lung cancer.'